...
机译:根据可重型食管鳞状细胞癌的新辅助化疗的改良内镜化疗的临床结果
Department of Gastroenterology and EndoscopyNational Cancer Center Hospital EastChiba Japan;
Endoscopy DivisionNational Cancer Center HospitalTokyo Japan;
Department of Gastroenterology and EndoscopyNational Cancer Center Hospital EastChiba Japan;
Endoscopy DivisionNational Cancer Center HospitalTokyo Japan;
Endoscopy DivisionNational Cancer Center HospitalTokyo Japan;
Department of GastroenterologyNational Cancer Center Hospital EastChiba Japan;
Gastrointestinal Medical Oncology DivisionsNational Cancer Center HospitalTokyo Japan;
Department of Esophageal SurgeryNational Cancer Center Hospital EastChiba Japan;
Department of Gastroenterology and EndoscopyNational Cancer Center Hospital EastChiba Japan;
endoscopic criteria; endoscopic evaluation; esophageal squamous cell carcinoma; neoadjuvant chemotherapy;
机译:根据可重型食管鳞状细胞癌的新辅助化疗的改良内镜化疗的临床结果
机译:CMISG1701:一项多中心前瞻性随机III期临床试验,比较了局部晚期可切除食管鳞状细胞癌(cT 3-4a N 0-1 M 0)的患者中新辅助放化疗与新辅助化疗后再进行微创食管切除术(NCT03001596)
机译:Neoadjuvant化疗用伊立康康和Nedaplatin在单一的循环中,然后在CT4可重型食管鳞状细胞癌上进行食道切除术:短期结果的前瞻性非扫描试验
机译:CCND1作为局部晚期头颈部鳞状细胞癌患者新辅助化疗的预测生物标志物
机译:通过综合癌症表观遗传学和基因组学鉴定食管鳞状细胞癌和鼻咽癌的11q和15q新型候选肿瘤抑制基因。
机译:CMISG1701:一项多中心前瞻性随机III期临床试验比较了局部晚期可切除食管鳞状细胞癌(cT3-4aN0-1M0)患者中新辅助放化疗与新辅助化疗后再进行微创食管切除术(NCT03001596)
机译:Neoadjuvant化疗和免疫治疗在当地可重置的晚期食管鳞状细胞癌中的疗效和安全性